SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The ...

Tandem Diabetes Care, Inc.’s TNDM Mobi insulin pump with Control-IQ technology is now fully compatible with both Dexcom’s DXCM G7 and G6 Continuous Glucose Monitoring (“CGM”) Systems. The world’s ...

It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...

“The commercial availability of this new offering is a testament to our decade-long partnership with Dexcom and shared commitment to continued leadership in advancing AID systems,” said Mark Novara, ...

DexCom, Inc. DXCM announced that its latest G7 continuous glucose monitoring (CGM) system can now connect with Tandem Diabetes Care's t:slim X2 insulin pump featuring Control-IQ technology. This ...

On Tuesday, DexCom and Animas, the insulin pump unit of Johnson & Johnson , announced they were amending their joint development agreement to extend outside of the U.S. According to a DexCom press ...

As part of the Tandem/DexCom deal, Tandem agreed to pay a $3 million technology licensing free upfront. The company will also cover any development, clinical and regulatory expenses DexCom faces. Once ...

Hybrid closed-loop systems are increasingly gaining recognition as a gold-standard option for diabetes management, and medtech makers are jumping at the opportunity to add their own artificial ...

MARKHAM, Ontario — Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ insulin pump ...